Develops oral drugs for obesity and hemophilia.
Jun 2026Revenue $4.88M/yrExpenses $37.8M/yr
No trendCash runway ≈ 3 months from Jun 2026
Figures by year
When will Rani Therapeutics Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.88M and expenses $37.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.63M | $39.9M | −$38.3M |
| Dec 2024 | $1.03M | $54.3M | −$53.3M |
| Dec 2023 | $0.00 | $66.1M | −$66.1M |
| Dec 2022 | $0.00 | $63.5M | −$63.5M |
| Dec 2021 | $2.72M | $54.3M | −$51.6M |
| Dec 2020 | $462K | $17.0M | −$16.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.